This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: The University of Texas System, Yale University. Active years: 2022-2026.
Company Filing History:
2 out of 5,633 
2 out of 1,365 
Years Active: 2022-2026
Title: Bruno Sinn: Innovator in Hormonal Therapy Research
Introduction
Bruno Sinn is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of hormonal therapy, particularly in relation to breast cancer treatment. With a total of 2 patents, his work focuses on improving the sensitivity of tumors to endocrine therapy.
Latest Patents
Bruno Sinn's latest patents include innovative methods for determining tumoral sensitivity to hormonal therapy. One of his patents introduces the sensitivity to endocrine therapy index (SETindex), which assesses estrogen receptor (ER) and progesterone receptor (PR)-related genes. This method may also consider the proportion of ER gene (ESR1) RNA transcripts containing mutations. Additionally, he has developed methods for treating breast cancer patients identified as sensitive to endocrine therapy based on the SETindex. Another patent presents the sensitivity to endocrine therapy index (SETER/PR index), which similarly evaluates tumoral sensitivity and provides treatment methods for breast cancer patients.
Career Highlights
Bruno Sinn has worked with prestigious institutions such as Yale University and The University of Texas System. His research has focused on enhancing the understanding of hormonal therapies and their effectiveness in treating breast cancer.
Collaborations
Bruno has collaborated with notable colleagues, including Rosanna Lau and Chunxiao Fu. Their combined efforts have contributed to advancements in the field of hormonal therapy.
Conclusion
Bruno Sinn's innovative work in hormonal therapy research has the potential to significantly impact breast cancer treatment. His patents reflect a commitment to improving patient outcomes through targeted therapeutic strategies.